[ad_1]
Rodney Varner, CEO of Genprex Inc. (NASDAQ: GNPX), informs proactive investors of the latest developments regarding the Texas-based company's non-small cell anti-cancer drug, including results from positive studies in humanized mice .
According to Varner, the study of the lead drug Oncoprex at the MD Anderson Cancer Center at the University of Texas was completed in April after examining the effects of the tumor suppressor gene TUSC2 found in Oncoprex in combination with immunotherapy.
Source link
